New drug ABBV-142 tested in healthy people for first time
NCT ID NCT06774313
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a single dose of the experimental drug ABBV-142 in 73 healthy adults to check its safety and how the body handles it. The study also included a small group of Han Chinese participants to see if there are any differences. Since this is a phase 1 trial in healthy volunteers, it does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABBV-142
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Acpru /Id# 271899
Grayslake, Illinois, 60030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?